On Monday, C4 Therapeutics Inc (CCCC) stock saw a modest uptick, ending the day at $6.45 which represents a slight increase of $0.84 or 14.97% from the prior close of $5.61. The stock opened at $5.58 ...
Morgan Stanley analyst Terence Flynn maintained a Hold rating on C4 Therapeutics (CCCC – Research Report) today and set a price target of ...
Seaport names Lauren White as CFO. Ms. White most recently served as CFO at ImmunoGen prior to its acquisition by AbbVie for ...
C4 Therapeutics, Inc. ( (CCCC) ) has released its Q3 earnings. Here is a breakdown of the information C4 Therapeutics, Inc. presented to its ...
Revenue exceeded analyst estimates significantly. Earnings per share (EPS) also surpassed analyst estimates by 12%. Looking ...
Shares of CCCC opened at $5.30 on Friday. C4 Therapeutics has a 52-week low of $1.06 and a 52-week high of $11.88. The firm has a market cap of $364.67 million, a price-to-earnings ratio of -2.24 ...
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. TipRanks is the most comprehensive data set of sell side ...
Oct. 15, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback